Clinical Trial Update: Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Ultra-Fast CD19 CAR-T cell therapy for refractory systemic lupus erythematosus is currently recruiting. The sponsor is Chongqi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Ultra-Fast CD19 CAR-T Therapy (CD19-targeted CAR-T cell therapy)

Snippet

Sponsor: Chongqing Precision Biotech Co., Ltd | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: RECRUITING